Shaily Engineering Plastics Limited has informed the Exchange about Transcript
SHAILY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shaily Engineering Plastics reported strong Q3 FY26 results with revenue of INR 251 crores, up 27% year-on-year, and EBITDA of INR 66 crores with margins expanding 310 basis points to 26.5%. PAT grew 48% YoY to INR 37 crores. For 9M FY26, revenue rose 32% to INR 754 crores and EBITDA jumped 76% to INR 218 crores, with margins at 29%. The Healthcare segment grew 139% in Q3 and now contributes 42% of revenue, while the Consumer segment declined 13% due to weak demand in Europe and the US. Key strategic updates include a new AED 130-150 million (INR 300-350 crores) facility in Abu Dhabi for pen and auto-injectors with 75 million units annual capacity, expected operational by Q4 FY28, taking total pen capacity to 150 million units. Management also onboarded 2 new GLP-1 customers, signed 2 new contracts with global pharma, and appointed a new COO for healthcare.
Strong quarterly performance with significant margin expansion and rapid healthcare growth signals positive momentum for the stock. The Abu Dhabi expansion nearly doubles pen injector capacity and positions the company to capitalize on the global GLP-1 opportunity, though the INR 300-350 crores capex and delayed line qualifications introduce near-term execution risks. The consumer business weakness remains a drag and requires a turnaround once US/EU trade pacts improve demand.